Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01866098 · ClinicalTrials.gov registry record · NA
Naltrexone for Antipsychotic-Induced Weight Gain
A NA study, sponsored by Yale University.
- Completed
- Registry status
- NA
- Development phase
- 144
- Enrollment target
NCT01866098 is a NA study that has completed, run by Yale University. The registered enrollment target is 144 participants.
The verdict
NCT01866098, a NA study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- NA
- Development phase
- 144 participants
- Enrollment target
Study Summary
This study is designed to look at the effects of naltrexone on weight loss in individuals treated with antipsychotic medications. Naltrexone is an FDA approved medication for the management of alcohol dependence and drug dependence, but has not been fully evaluated for its effect on weight loss in individuals with severe mental illness (i.e. schizophrenia, schizoaffective disorder, bipolar disorder etc.) The purpose of this study is to find out how effective two different doses of oral naltrexone is on reducing body weight when compared to placebo (an inactive substance or "sugar pill").
Interventions
- DRUG Placebo
- DRUG Naltrexone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 144 participants |
| Start Date | 2013-05 |
| Est. Completion | 2019-04-07 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01866098
The ClinicalTrials.gov registry entry for NCT01866098 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 144 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01866098 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01866098 about?
NCT01866098 is a clinical study titled "Naltrexone for Antipsychotic-Induced Weight Gain". This study is designed to look at the effects of naltrexone on weight loss in individuals treated with antipsychotic medications. Naltrexone is an FDA approved medication for the management of alcohol dependence and drug dependence, but has not been fully evaluated for its effect on weight loss in i...
What is the current status of trial NCT01866098?
This trial is currently completed. It is a NA study. The enrollment target is 144 participants. The study started on 2013-05. Estimated completion is 2019-04-07.
What interventions are being tested in trial NCT01866098?
The interventions under investigation include: Placebo (DRUG), Naltrexone (DRUG).
Who is sponsoring clinical trial NCT01866098?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.